Organ Preservation Companies

Top Industry Leaders in the Organ Preservation Market

Organ Preservation Key Companies

Oct 2023: For a maximum of $5.8 billion, Bristol-Myers Squibb said that it will buy cancer manufacturer Mirati Therapeutics. The company intends to partially offset the revenue loss anticipated from patent expirations in the coming years by broadening its oncology business and acquiring new medications. Bristol will acquire Mirati's portfolio of medications, which includes the December-approved lung cancer treatment Krazati, that target the genetic causes of tumors. The business was also drawn to a second molecule, MRTX1719, which may be employed in certain lung cancer cases. The business announced its plan to purchase Mirati for cash for $58 per share, or roughly $4.8 billion.

Jul 2023: The heart-lung machine priming research by organ transplant medtech startup XVIVO Perfusion AB has ended, and the business has announced that it will now assess the product's commercial potential. In 2017, the solution known as PrimECC showed encouraging safety outcomes. The new trial was started in 2020, and the Swedish company hoped it would increase the size of the clinical dataset for PrimECC. However, XVIVO identified general difficulties in locating recruiting locations, non-fulfillment of criteria, and COVID-19-related patient enrollment issues as explanations for the trial's failures. The 2016 CE-marked solution keeps air bubbles from getting into the bloodstream by being introduced to heart-lung machines used in cardiopulmonary bypass surgeries. Right now, saline is applied.

List of Organ Preservation Key companies in the market